Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for RIGL
-0.08 (-2.36%)
Real-time:   1:34PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.26 - 3.35
52 week 2.31 - 5.00
Open 3.34
Vol / Avg. 138,144.00/445,441.00
Mkt cap 289.73M
P/E     -
Div/yield     -
EPS -0.98
Shares 87.53M
Beta 1.00
Inst. own 90%
Aug 5, 2014
Q2 2014 Rigel Pharmaceuticals Inc. Earnings Release - 9:30AM EDT - Add to calendar
Jun 18, 2014
Rigel Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Jun 3, 2014
Rigel Pharmaceuticals Inc. at Jefferies Global Healthcare Conference - Webcast
May 20, 2014
Rigel Pharmaceuticals Inc. Annual Meeting of Stockholders
May 7, 2014
Q1 2014 Rigel Pharmaceuticals Inc. Earnings Release
May 6, 2014
Rigel Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -1245.13%
Operating margin - -1251.32%
EBITD margin - -1191.58%
Return on average assets -41.67% -33.21%
Return on average equity -45.11% -35.80%
Employees 129 -
CDP Score - -


1180 Veterans Boulevard
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. As of December 31, 2011, product development programs included fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) with its partner AstraZeneca (AZ); R343, an inhaled SYK inhibitor for asthma and R333, a topical janus kinase (JAK)/SYK inhibitor for discoid lupusboth of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye. In December 2012, the Company initiated a Phase 1 clinical study of R348, a topical ophthalmic JAK/SYK inhibitor, as a potential therapeutic for chronic dry eye.

Officers and directors

James M. Gower Chairman of the Board, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Raul R. Rodriguez President, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ryan D. Maynard Chief Financial Officer, Executive Vice President
Age: 43
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Donald G. Payan M.D. Executive Vice President, President - Discovery and Research, Director
Age: 64
Bio & Compensation  - Reuters
Elliot B. Grossbard M.D. Executive Vice President, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 58
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 63
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters